---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-037298"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-09-22T12:05:08+00:00"
generated_at: "2026-09-22T12:10:30.412616+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech publishes Phase 2 VERSATILE-002 results in JAMA Oncology; mOS 39.3 months in ICI-naive HNSCC

## Summary
- mOS of 39.3 months for CPS≥1 ICI-naive patients vs 17.9 months for pembrolizumab SOC.
- ORR 36% vs 19% published for pembro; 13.8% Grade≥3 TRAEs vs 17%.
- PIPE financing of up to $22.3M led by Nant Capital; NantWorks gets one-year exclusive license negotiation right for PDS0101.
- Company prioritizes PDS0301 in mCRC and pursues partnership for PDS0101.

## SEC filing metadata
- accession: 0001140361-26-037298
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-09-22T12:05:08+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/0001140361-26-037298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/ef20082545_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-037298
- JSON: https://secwatch.observer/filing/0001140361-26-037298.json
- Plain text: https://secwatch.observer/filing/0001140361-26-037298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.